The AlphaLISA® immunoassay kit for human cytochrome C (CYCS) enables the quantitative determination of cytochrome C in buffer, liver and kidney cytosol, and liver mitochondria fraction using a homogeneous AlphaLISA assay (no wash steps).
You successfully added item(s) to your cart
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Cytochrome C is also known as somatic CYCS; cytochrome complex, somatic; HCS; CYC; THC4. It is a - ~12 kDa protein consisting of a single 104 amino hemeprotein. It is a highly conserved protein across the spectrum of species and has been used as a model protein for molecular evolution. Cytochrome C is found loosely associated with the inner membrane of the mitochondrion and functions as a central component of the electron transport chain in mitochondria. It has several functions such as electron transport, catalyze several redox reactions and involvement in initiation of apoptosis.
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 Assay Points|
Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more data points from each sample and eliminate tedious wash steps? Find out how AlphaLISA® assay technology, combined with the EnVision® multimode plate reader, provides a fast, powerful, homogeneous platform for screening potential inhibitors of PD-L1 (a protein associated with breast cancer tumor cells) expression in human cells.